Department of Biomedical Science and Technology, Konkuk University, Seoul 143-701, Korea.
J Neurosci. 2012 Sep 26;32(39):13454-69. doi: 10.1523/JNEUROSCI.1292-12.2012.
Abnormal deposition and intercellular propagation of α-synuclein plays a central role in the pathogenesis of disorders such as Parkinson's Disease (PD) and dementia with Lewy bodies (DLB). Previous studies demonstrated that immunization against α-synuclein resulted in reduced α-synuclein accumulation and synaptic loss in a transgenic (tg) mouse model, highlighting the potential for immunotherapy. However, the mechanism by which immunization prevents synucleinopathy-associated deficits remains unknown. Here, we show that antibodies against α-synuclein specifically target and aid in clearance of extracellular α-synuclein proteins by microglia, thereby preventing their actions on neighboring cells. Antibody-assisted clearance occurs mainly in microglia through the Fcγ receptor, and not in neuronal cells or astrocytes. Stereotaxic administration of antibody into the brains of α-synuclein tg mice prevented neuron-to-astroglia transmission of α-synuclein and led to increased localization of α-synuclein and the antibody in microglia. Furthermore, passive immunization with α-synuclein antibody reduced neuronal and glial accumulation of α-synuclein and ameliorated neurodegeneration and behavioral deficits associated with α-synuclein overexpression. These findings provide an underlying mechanistic basis for immunotherapy for PD/DLB and suggest extracellular forms of α-synuclein as potential therapeutic targets.
异常的α-突触核蛋白沉积和细胞间传播在帕金森病 (PD) 和路易体痴呆 (DLB) 等疾病的发病机制中起核心作用。先前的研究表明,针对α-突触核蛋白的免疫接种可导致转基因 (tg) 小鼠模型中α-突触核蛋白的积累减少和突触丧失,突出了免疫疗法的潜力。然而,免疫接种防止突触核蛋白病相关缺陷的机制仍不清楚。在这里,我们表明针对α-突触核蛋白的抗体特异性靶向并有助于小胶质细胞清除细胞外α-突触核蛋白蛋白,从而防止其对邻近细胞的作用。抗体辅助清除主要通过 Fcγ 受体发生在小胶质细胞中,而不是在神经元细胞或星形胶质细胞中。通过立体定向将抗体注入α-突触核蛋白 tg 小鼠的大脑中,可防止α-突触核蛋白从神经元到星形胶质细胞的传递,并导致α-突触核蛋白和抗体在小胶质细胞中的定位增加。此外,用α-突触核蛋白抗体进行被动免疫可减少神经元和星形胶质细胞中α-突触核蛋白的积累,并改善与α-突触核蛋白过表达相关的神经退行性变和行为缺陷。这些发现为 PD/DLB 的免疫疗法提供了潜在的机制基础,并表明细胞外形式的α-突触核蛋白可能是潜在的治疗靶点。